DOCSLIB.ORG

(19) United States (12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(19) United States (12) Patent Application Publication (10) Pub US 20050221029A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0221029 A1 Cater et al. (43) Pub. Date: Oct. 6, 2005 (54) OXYGEN SCAVENGING SYSTEM Publication Classi?cation (76) Inventors: Mark W. Cater, Prairie, MN (US); (51) Int. Cl? ..................................................... .. B65D 1/00 Donald A. Grindsta?', Apple Valley, (52) US. Cl. .......................................................... .. 428/341 MN (US) (57) ABSTRACT Correspondence Address: The oxygen scavenging system of the subject invention NAWROCKI, ROONEY & SIVERTSON contemplates a composition, system and appurtenant meth SUITE 401, BROADWAY PLACE EAST odology for substantially eliminating elemental oxygen 3433 BROADWAY STREET NORTHEAST from packaged oxygen sensitive products. The composition MINNEAPOLIS, MN 554133009 or scavenging agent includes an oxidoreductase enZyme, a suitable energy source or substrate for the enZyme, and a (21) Appl. No.: 10/518,292 buffer. The composition binds oxygen When exposed to moisture, thereby reducing the level of oxygen in a closed (22) PCT Filed: Jun. 17, 2003 (e.g., sealed) space such as a food package or the like. More particularly and preferably, the composition includes glu (86) PCT No.: PCT/US03/19029 cose oxidase in an amount of betWeen 1 and 100 activity units (U) per gram, catalase in an amount of betWeen 1 and Related US. Application Data 300 activity units (U) per gram, dextrose in an amount of betWeen about 20 and 99 percent by Weight, and sodium (60) Provisional application No. 60/389,246, ?led on Jun. bicarbonate in an amount of betWeen about 1 and 80 percent 17, 2002. by Weight. US 2005/0221029 A1 Oct. 6, 2005 OXYGEN SCAVENGING SYSTEM or sachets. DraWbacks associated With such approach have included, but are not limited to, careful sealed storage of the [0001] This is a regular application ?led under 35 U.S.C. §111(a) claiming priority under 35 U.S.C. §119(e)(1), of sealed package so as to prevent activation upon exposure to provisional application Ser. No. 60/389,246 having a ?ling oxygen, the expense of such system, and the fact that iron oxide creates heat as it binds oxygen, a less than desirable date of Jun. 17, 2002 and ?led under 35 U.S.C. §111(b). outcome. TECHNICAL FIELD [0008] A further, Widely practiced means of binding oxy [0002] The present invention relates generally to oxygen gen is the use of the enZyme glucose oxidase, in combination scavenging (i.e., targeting and reduction/elimination) for With a suitable glucose source, if necessary. Used alone, oxygen sensitive products, more particularly to a composi glucose oxidase creates or generates peroxide (i.e., hydrogen tion, system, and attendant methodology for removing oxy peroxide is a reaction product). Peroxide may have detri gen from stored oxygen sensitive products such as food, mental effects on the product in the package and its presence pharmaceuticals, etc. may limit the further binding of oxygen by the glucose oxidase. The addition of an appropriate amount of catalase BACKGROUND OF INVENTION enZyme has been used to break doWn the peroxide. This Works acceptably in many systems Where the glucose oxi [0003] The quality and character of products, Whether they dase/catalase mixture is spread over a surface, and the be consumables, intermediates, etc., remain of utmost packaged product acts as a pH buffer, maintaining an accept importance. Furthermore, it is Well knoWn that freshness and able pH range Where the oxygen binding reaction proceeds, shelf life can be key or determinative considerations in one’s hoWever, efforts to use such enZymatic formulations in a selection calculus. Although degradation is a natural phe dispersed or contained form on iron rich products have been nomenon and can in fact be desirable, it more often than not unsuccessful because of discoloration of the product. is a condition sought to be controlled, more particularly eliminated, or at least sloWed doWn, as is almost alWays the [0009] It is believed that the lack of success With such case With perishable goods. enZymatic formulations is most likely due to the oxygen binding reaction being self-limited by the change in pH [0004] Many substances, especially foods, bene?t from Within the bag or sachet (see generally EnZyme Technology, storage in an environment free from, or containing a very Chaplin & Bucke, Cambridge University Press, 1990). As loW level of, free oxygen (O2). Oxygen is knoWn to cause enZymes are amphoteric molecules containing a large num oxidative damage to many products, particularly, but not ber of acid and basic groups, mainly situated on their limited too, fats and oils. When exposed to oxygen many fats surface, the charges on these groups Will vary, according to and oils oxidiZe, With a rancid ?avor imparted to the fat or their acid dissociation constants, With the pH of their envi oil, other qualities and the general character of the oil being ronment. In addition to the reactivity of the catalytically thereby altered. As the oxidation of fats and oils appears to active groups, this directly impacts the total net charge of the be a self-catalytic reaction (i.e., upon initiation, the reaction enZymes, and the distribution of charge on their exterior proceeds relatively quickly, and fully), preventing or retard surfaces. These effects are especially important in the vicin ing the oxidation in the ?rst place is paramount. Further ity of the active sites. Thus, in combination, the variability more, and of equal importance, is the fact that oxygen of the charges With pH (i.e., the charges being a function of supports the groWth of microorganisms Which cause spoil pH) affect the activity, structural stability and solubility of age and discoloration of the product. the enZyme, and have thus been limitations upon this form [0005] Current packaging methods and packaging mate of oxygen scavenging system. rials enable the elimination of much of the oxygen via time [0010] Although the use of a buffer to stabiliZe a liquid consuming vacuum and head space gas ?ushing processes. glucose oxidase system during storage is described in Euro In most cases, some amount of oxygen remains in the pean patent EP0418940, it does not address oxygen removal package. Removal of oxygen from packages of products or buffering of the system during enZyme activity. Similarly, Where gas is trapped Within the product (eg bread or pasta) US. Pat. Nos. 2,765,233 and 5,064,698 teach the addition to is especially difficult. Furthermore, most packaging materi glucose oxidase directly to packaging materials in various als are not impervious to oxygen penetration (i.e., package Ways, namely via encapsulation in polymeric beads. Be this ingress: over time, oxygen leaks through the packaging as it may, there are practical limitations on the amount of material, and into the package). glucose oxidase that can be applied to food Wrappers/ [0006] To retard oxidation, anti-oxidants have been added containers utiliZing heretofore knoWn techniques. No com to foods. For instance, BHA [(1,1-dimethylethyl)-4-meth mercially acceptable oxygen scavenging agent, suitable for oxy phenol] and BHT [2,6-di-tert-butyl-para-cresol] are direct application or subsequently introduced post packag common anti-oxidant food additives. HoWever, BHA is ing, Which virtually eliminates (i.e., binds) oxygen present regarded as moderately toxic by ingestion, and even though and Which further insigni?cantly changes or modi?es the BHT is considered to have loW toxicity, the use in foods of quality or character of the perishable (e.g., does not discolor either of these compounds is limited. While these com the item), has been heretofore disclosed. pounds have contributed greatly to the food industry by reducing the amount of food that must be discarded, some SUMMARY OF THE INVENTION consumers prefer foods Without them. [0011] The subject oxygen scavenging system is generally [0007] In a broader sense, the binding/scavenging of oxy directed to the elimination of oxygen from packaged oxygen gen has typically been accomplished With iron oxide, more sensitive products Where moisture is present of may become particularly, iron oxide packaged Within gas permeable bags present. An oxygen scavenging composition of the subject US 2005/0221029 A1 Oct. 6, 2005 invention includes an enzyme system (e.g., an oxidoreduc Which catalyses the oxidation of [3-D-glucose to D-glucono tase enzyme), a suitable energy source for the enZyme 1,5-lactone, Which spontaneously hydrolyZes, non-enZymi system, and a buffer. The composition, Which enhances the cally, to gluconic acid, using molecular oxygen, With a shelf-life of a packaged product, is suitable for direct appli release of hydrogen peroxide as folloWs: cation to the product of the packaged product With no consumer detectable change in product character. The com position binds oxygen When exposed to moisture, thereby [0016] Hexose oxidase, Which also functions as an effec reducing the level of oxygen in a closed (e.g., sealed) space tive oxygen scavenger and is less speci?c than glucose such as a food package or the like. The system of the subject oxidase, is an enZyme Which in the presence of oxygen is invention contemplates the scavenging composition in com capable of oxidiZing D-glucose, and several other reducing bination With a discrete Water permeable “housing” Within sugars (i.e., substrates) including, but not limited to maltose, Which the composition is contained, or as an integral ele lactose and cellobiose, to their corresponding lactones, With ment or component of a perishable storage container or the subsequent hydrolysis to the respective aldobionic acids like. More speci?c features and advantages Will become (e.g., in the case of D-glucose, gluconic acid). Accordingly, apparent With reference to the DETAILED DESCRIPTION hexose oxidase differs from another oxidoreductases (e.g., OF THE INVENTION, and appended claims.
Load more

Recommended publications
  • Hexose Oxidase from Chondrus Crispus Expressed in Hansenula Polymorpha
    Chemical and Technical Assessment 63rdJECFA Hexose Oxidase from Chondrus Crispus expressed in Hansenula Polymorpha CHEMICAL AND TECHNICAL ASSESSMENT (CTA) Prepared by Jim Smith and Zofia Olempska-Beer © FAO 2004 1 Summary Hexose oxidase (HOX) is an enzyme that catalyses the oxidation of C6-sugars to their corresponding lactones. A hexose oxidase enzyme produced from a nonpathogenic and nontoxigenic genetically engineered strain of the yeast Hansenula polymorpha has been developed for use in several food applications. It is encoded by the hexose oxidase gene from the red alga Chondrus crispus that is not known to be pathogenic or toxigenic. C. crispus has a long history of use in food in Asia and is a source of carrageenan used in food as a stabilizer. As this alga is not feasible as a production organism for HOX, Danisco has inserted the HOX gene into the yeast Hansenula polymorpha. The information about this enzyme is provided in a dossier submitted to JECFA by Danisco, Inc. (Danisco, 2003). Based on the hexose oxidase cDNA from C. crispus, a synthetic gene was constructed that is more suitable for expression in yeast. The synthetic gene encodes hexose oxidase with the same amino acid sequence as that of the native C. crispus enzyme. The synthetic gene was combined with regulatory sequences, promoter and terminator derived from H. polymorpha, and inserted into the well-known plasmid pBR322. The URA3 gene from Saccharomyces cerevisiae (Baker’s yeast) and the HARS1 sequence from H. polymorpha were also inserted into the plasmid. The URA3 gene serves as a selectable marker to identify cells containing the transformation vector.
    [Show full text]
  • (FAD) and Flavin Mononucleotide (FMN) to Enzymes: the Current State of Affairs
    Protein Science (1998). 77-20. Cambridge University Press. Printed in the USA. Copyright 0 1998 The Protein Society REVIEW Covalent attachment of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) to enzymes: The current state of affairs MARTIN MEWIES,' WILLIAM S. McINTIRE,~.~AND NIGEL S. SCRUTTON' ' Department of Biochemistry, University of Leicester, Adrian Building, University Road, Leicester LEI 7RH UK * Molecular Biology Division, Department of Veterans Affairs Medical Center, San Francisco, California 94121 Department of Biochemistry and Biophysics and Department of Anesthesia, University of California, San Francisco, California 94565 (RECEIVEDMay 29, 1997; ACCEFTEDJuly 18, 1997) Abstract The first identified covalent flavoprotein, a component of mammalian succinate dehydrogenase, was reported 42 years ago. Since that time, more than 20 covalent flavoenzymes have been described, each possessing one of five modes of FAD or FMN linkage to protein. Despite the early identification of covalent flavoproteins, the mechanisms of covalent bond formation and the roles of the covalent links are only recently being appreciated. The main focus of this review is, therefore, one of mechanism and function, in addition to surveying the types of linkage observed and the methods employed for their identification. Case studies are presented for a variety of covalent flavoenzymes, from which general findings are beginning to emerge. Keywords: covalent flavoproteins; flavin adenine dinucleotide; flavin mononucleotide; flavinylation; redox cofactors Cofactors are recruited by protein molecules to extend the chem- lipoate-protein ligases (Brookfield et al., 1991; Moms et al., 1994), istry available within the active sites of enzymes. The chemistries respectively. In a similar fashion, a heme cytochrome c lyase (Steiner displayed are variable and the range of protein-specific cofactors et al., 1996) is responsible for the covalent addition of heme to two available bears testimony to the types of biological reaction achieved Cys residues via thioether linkages.
    [Show full text]
  • Enzyme DHRS7
    Toward the identification of a function of the “orphan” enzyme DHRS7 Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Selene Araya, aus Lugano, Tessin Basel, 2018 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt (Fakultätsverantwortlicher) und Prof. Dr. Michael Arand (Korreferent) Basel, den 26.6.2018 ________________________ Dekan Prof. Dr. Martin Spiess I. List of Abbreviations 3α/βAdiol 3α/β-Androstanediol (5α-Androstane-3α/β,17β-diol) 3α/βHSD 3α/β-hydroxysteroid dehydrogenase 17β-HSD 17β-Hydroxysteroid Dehydrogenase 17αOHProg 17α-Hydroxyprogesterone 20α/βOHProg 20α/β-Hydroxyprogesterone 17α,20α/βdiOHProg 20α/βdihydroxyprogesterone ADT Androgen deprivation therapy ANOVA Analysis of variance AR Androgen Receptor AKR Aldo-Keto Reductase ATCC American Type Culture Collection CAM Cell Adhesion Molecule CYP Cytochrome P450 CBR1 Carbonyl reductase 1 CRPC Castration resistant prostate cancer Ct-value Cycle threshold-value DHRS7 (B/C) Dehydrogenase/Reductase Short Chain Dehydrogenase Family Member 7 (B/C) DHEA Dehydroepiandrosterone DHP Dehydroprogesterone DHT 5α-Dihydrotestosterone DMEM Dulbecco's Modified Eagle's Medium DMSO Dimethyl Sulfoxide DTT Dithiothreitol E1 Estrone E2 Estradiol ECM Extracellular Membrane EDTA Ethylenediaminetetraacetic acid EMT Epithelial-mesenchymal transition ER Endoplasmic Reticulum ERα/β Estrogen Receptor α/β FBS Fetal Bovine Serum 3 FDR False discovery rate FGF Fibroblast growth factor HEPES 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid HMDB Human Metabolome Database HPLC High Performance Liquid Chromatography HSD Hydroxysteroid Dehydrogenase IC50 Half-Maximal Inhibitory Concentration LNCaP Lymph node carcinoma of the prostate mRNA Messenger Ribonucleic Acid n.d.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Masterarbeit / Master's Thesis
    MASTERARBEIT / MASTER’S THESIS Titel der Masterarbeit / Title of the Master‘s Thesis „Physiology, Metabolism and Biohydrogen Production of Desulfurococcus fermentans“ verfasst von / submitted by Barbara Reischl, BSc angestrebter akademischer Grad / in partial fulfilment of the requirements for the degree of Master of Science (MSc) Wien, 2016 / Vienna 2016 Studienkennzahl lt. Studienblatt / A 066 830 degree programme code as it appears on the student record sheet: Studienrichtung lt. Studienblatt / Molecular Microbiology, Microbial Ecology degree programme as it appears on and Immunobiology the student record sheet: Betreut von / Supervisor: Univ.-Prof. Dipl.-Biol. Dr. Christa Schleper Mitbetreut von / Co-Supervisor: Mag. Mag. Dr. Simon Karl-Maria Rasso Rittmann, Bakk. 2 Table of Contents 1. Introduction .......................................................................................................... 5 1.1 Role of Biohydrogen ................................................................................................ 5 1.2 Hydrogenases ......................................................................................................... 6 1.3 Characteristics of Desulfurococcus fermentans ....................................................... 7 1.4 Aims of this Study ................................................................................................... 8 2. Material and Methods ............................................................................................ 9 2.1 Chemicals ..............................................................................................................
    [Show full text]
  • University of Groningen Exploring the Cofactor-Binding and Biocatalytic
    University of Groningen Exploring the cofactor-binding and biocatalytic properties of flavin-containing enzymes Kopacz, Malgorzata IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2014 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Kopacz, M. (2014). Exploring the cofactor-binding and biocatalytic properties of flavin-containing enzymes. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 29-09-2021 Exploring the cofactor-binding and biocatalytic properties of flavin-containing enzymes Małgorzata M. Kopacz The research described in this thesis was carried out in the research group Molecular Enzymology of the Groningen Biomolecular Sciences and Biotechnology Institute (GBB), according to the requirements of the Graduate School of Science, Faculty of Mathematics and Natural Sciences.
    [Show full text]
  • Metabolic Network-Based Stratification of Hepatocellular Carcinoma Reveals Three Distinct Tumor Subtypes
    Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes Gholamreza Bidkhoria,b,1, Rui Benfeitasa,1, Martina Klevstigc,d, Cheng Zhanga, Jens Nielsene, Mathias Uhlena, Jan Borenc,d, and Adil Mardinoglua,b,e,2 aScience for Life Laboratory, KTH Royal Institute of Technology, SE-17121 Stockholm, Sweden; bCentre for Host-Microbiome Interactions, Dental Institute, King’s College London, SE1 9RT London, United Kingdom; cDepartment of Molecular and Clinical Medicine, University of Gothenburg, SE-41345 Gothenburg, Sweden; dThe Wallenberg Laboratory, Sahlgrenska University Hospital, SE-41345 Gothenburg, Sweden; and eDepartment of Biology and Biological Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden Edited by Sang Yup Lee, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, and approved November 1, 2018 (received for review April 27, 2018) Hepatocellular carcinoma (HCC) is one of the most frequent forms of of markers associated with recurrence and poor prognosis (13–15). liver cancer, and effective treatment methods are limited due to Moreover, genome-scale metabolic models (GEMs), collections tumor heterogeneity. There is a great need for comprehensive of biochemical reactions, and associated enzymes and transporters approaches to stratify HCC patients, gain biological insights into have been successfully used to characterize the metabolism of subtypes, and ultimately identify effective therapeutic targets. We HCC, as well as identify drug targets for HCC patients (11, 16–18). stratified HCC patients and characterized each subtype using tran- For instance, HCC tumors have been stratified based on the uti- scriptomics data, genome-scale metabolic networks and network lization of acetate (11). Analysis of HCC metabolism has also led topology/controllability analysis.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Oxidative Enzymes As Sustainable Industrial Biocatalysts 2010
    Oxidative Enzymes as Sustainable Industrial Biocatalysts 2010 STUCTURE-FUNCTION OF FLAVOENZYMES OF INDUSTRIAL INTEREST W.J.H. van Berkel Laboratory of Biochemistry. Wageningen University. Wageningen. The Netherlands E‐mail: [email protected] 1. Introduction Flavoenzymes are attractive biocatalysts because of the selectivity, controllability and efficiency of their reactions. Flavoenzymes typically contain a non‐covalently bound FMN or FAD cofactor involved in redox chemistry (van Berkel 2008). In some flavoenzymes, the isoalloxazine moiety of the flavin is covalently linked to the polypeptide chain (Hefti et al. 2003; Heuts et al. 2009). This can be beneficial for cofactor economy, protein stability, and the enzyme oxidation power. Flavoenzymes constitute about 2% of all enzymes and can be classified according to sequence, fold, and function. Here we focus on the structure‐function of flavoenzymes that are of interest for applications in the pharmaceutical, fine‐chemical and food industries. 2. Flavoprotein reductases Flavoprotein reductases primarily use NAD(P)H as electron donor and pass these electrons to a protein substrate or another electron acceptor. Flavoprotein reductases have long been ignored for biocatalytic applications, but this scenario has changed since the characterization of a number of members of the Old Yellow Enzyme (OYE) family. Ene reductases of the OYE family catalyze the asymmetric reduction of activated α,β‐unsaturated alkenes to the corresponding alkanes yielding valuable products containing one or two chiral carbon centres. Combining the ene reductases with a suitable NAD(P)H recycling catalyst enables highly stereoselective alkene reductions on a preparative scale that are difficult to perform by conventional means (Stuermer et al.
    [Show full text]
  • Carbon Source Feeding Strategies for Recombinant Protein Expression in Pichia Pastoris and Pichia Methanolica
    African Journal of Biotechnology Vol. 9(15), pp. 2173-2184, 12 April, 2010 Available online at http://www.academicjournals.org/AJB ISSN 1684–5315 © 2010 Academic Journals Review Carbon source feeding strategies for recombinant protein expression in Pichia pastoris and Pichia methanolica Raúl A. Poutou-Piñales1, 4*, Henry A. Córdoba-Ruiz2, Luis A. Barrera-Avellaneda3 and Julio M. Delgado-Boada4 1Laboratorio de Biotecnología Aplicada, Grupo de Biotecnología Ambiental e Industrial (GBAI), Departamento de Microbiología. Facultad de Ciencias, Pontificia Universidad Javeriana (PUJ). Bogota, D.C., Colombia. 2Departamento de Química. Facultad de Ciencias, Pontificia Universidad Javeriana (PUJ). Bogota, D.C., Colombia. 3Instituto de Errores Innatos del Metabolismo (IEIM), Pontificia Universidad Javeriana (PUJ). Bogota D.C., Colombia. 4Biotechnova Ltda. Bogota, D.C. Colombia. Accepted 28 December, 2009 Pichia pastoris and Pichia methanolica have been used as expression systems for the production of recombinant protein. The main problems of the production are the slow hierarchic consumption of ethanol and acetate which cause toxicity problems due to methanol accumulation when this surpasses 0.5 gl-1. In some cases, the laboratory scale cultures does not show the methanol accumulation problems because the cells are usually washed before changing the depleted carbon source culture media, by a fresh one, supplemented with methanol; a strategy that is clearly inapplicable in the industrial productions. Other authors use to feed the methanol before the depletion of glycerol or D- glucose, but this practice does not guaranty the ethanol and acetate fast consumption; leading to methanol accumulation and toxicity problems. It was concluded that pre-induction stage strategy should be studied in detail and that it is very important to start the induction stage with a concentration of biomass as great as possible.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0094384 A1 Vreeke Et Al
    US 2003OO94384A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0094384 A1 Vreeke et al. (43) Pub. Date: May 22, 2003 (54) REAGENTS AND METHODS FOR Related U.S. Application Data DETECTING ANALYTES, AND DEVICES COMPRISING REAGENTS FOR DETECTING (60) Provisional application No. 60/318,716, filed on Sep. ANALYTES 14, 2001. Publication Classification (76) Inventors: Mark S. Vreeke, Houston, TX (US); Mary Ellen Warchal-Windham, (51) Int. Cl. ................................................ G01N 27/327 Osceola, IN (US); Christina Blaschke, (52) U.S. Cl. ................................... 205/777.5; 204/403.01 White Pigeon, MI (US); Barbara J. Mikel, Mishawaka, IN (US); Howard A. Cooper, Elkhart, IN (US) (57) ABSTRACT Reagents for detecting an analyte are described. A reagent Correspondence Address: comprises (a) an enzyme Selected from the group consisting Jerome L. Jeffers, Esq. of a flavoprotein, a quinoprotein, and a combination thereof; Bayer Corporation and (b) a mediator Selected from the group consisting of a P.O. BOX 40 phenothiazine, a phenoxazine, and a combination thereof. In Elkhart, IN 46515-0040 (US) addition, reagents having good Stability to radiation Steril ization are described. Electrochemical Sensors and Sampling devices comprising Such reagents, methods of producing a (21) Appl. No.: 10/231,539 Sterilized device including Such reagents, and methods for detecting an analyte which utilize Such reagents are (22) Filed: Sep. 3, 2002 described as well. Layer 1 Layer 2 Layer3 Laminated Structure Patent Application Publication May 22, 2003. Sheet 1 of 6 US 2003/0094384 A1 FIG. 1 Layer 1 Layer 2 Layer3 Laminated Structure Patent Application Publication May 22, 2003.
    [Show full text]
  • Supplemental Figures 04 12 2017
    Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
    [Show full text]